|
EP3532496A1
|
|
Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
|
|
AU2015203660A1
|
|
Process to diagnose or treat brain injury
|
|
WO2015134551A1
|
|
Micro rna markers for diagnosis of a neurological condition
|
|
WO2015066211A1
|
|
Uch-l1 isoforms, assays and devices for detection of a neurological condition
|
|
US2015141528A1
|
|
Neural specific s100b for biomarker assays and devices for detection of a neurological condition
|
|
US2014275294A1
|
|
Devices and methods for biomarker detection process and assay of liver injury
|
|
US2014342381A1
|
|
Devices and methods for biomarker detection process and assay of neurological condition
|
|
US2014024053A1
|
|
Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
|
|
US2014018299A1
|
|
Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury
|
|
WO2011160096A2
|
|
Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
|
|
CN102918397A
|
|
Markers and assays for detection of neurotoxicity
|
|
WO2012141674A2
|
|
Compositions and methods relating to argininosuccinate synthetase
|
|
CA2774173A1
|
|
Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
|
|
WO2011011334A2
|
|
SYNERGISTIC BIOMARKER ASSAY OF NEUROLGICAL CONDITION USING S-100β
|
|
EP3355059A2
|
|
Biomarker assay of neurological condition
|
|
EP2324360A2
|
|
Biomarker detection process and assay of neurological condition
|
|
AU2009236057A1
|
|
An antibody bound synthetic vesicle containing active agent molecules
|
|
CA2715248A1
|
|
Process to diagnose or treat brain injury
|
|
AU2005238446A1
|
|
Neural proteins as biomarkers for nervous system injury and other neural disorders
|
